Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFUZOSIN HYDROCHLORIDE vs CIMZIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
Crohn's disease (FDA approved for adults with moderately to severely active disease),Rheumatoid arthritis (FDA approved for adults with moderately to severely active disease),Psoriatic arthritis (FDA approved for adults),Ankylosing spondylitis (FDA approved for adults),Plaque psoriasis (off-label use),Axial spondyloarthritis (off-label use)
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Certolizumab pegol is a monoclonal antibody fragment that is not metabolized by cytochrome P450 enzymes. It is degraded by proteolysis into small peptides and amino acids.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Not applicable (monoclonal antibody); typically does not bind to serum proteins other than target antigen.
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
~5.7 L (approx. 0.08 L/kg for a 70 kg patient), indicating predominant distribution in vascular space with limited extravascular penetration.
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
Subcutaneous: ~80% (range 63-92%) relative to intravenous administration.
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
No dose adjustment required for renal impairment. Not studied in severe renal impairment.
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
No dose adjustment required for hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C).
Not established; safety and efficacy in children <18 years have not been studied.
Not approved for use in pediatric patients. Safety and efficacy not established.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
No specific dose adjustment in elderly; use with caution due to increased infection risk.
None.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Serious infections (reactivation of TB, fungal infections, bacterial sepsis), malignancies (including lymphoma and non-melanoma skin cancer), hepatitis B virus reactivation, demyelinating disease (e.g., multiple sclerosis), congestive heart failure (new onset or exacerbation), hematologic abnormalities (pancytopenia, aplastic anemia), hypersensitivity reactions (including anaphylaxis), and lupus-like syndrome.
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
Active serious infection, including sepsis, tuberculosis, and opportunistic infections. Known hypersensitivity to certolizumab pegol or any of its components.
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
No known food interactions. Take with or without food. No dietary restrictions required.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no increased risk of major birth defects. Limited data in second and third trimesters; theoretical risk of immunosuppression in fetus. No known teratogenic effect in animal studies.
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
Minimal transfer into breast milk due to high molecular weight and PEGylation. M/P ratio not established. Consider benefits of breastfeeding vs risk of infant exposure. American Academy of Pediatrics considers compatible with breastfeeding.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
No standard dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to low placental transfer. Continue standard dosing; delay live vaccines in infants for 6 months after last maternal dose.
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. It lacks an Fc region, which reduces placental transfer, making it a preferred biologic for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease during pregnancy. Administer subcutaneously. Monitor for infections, including TB reactivation. Do not administer live vaccines concurrently. Injection site reactions are common; pre-medication with antihistamines may reduce them.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
Do not receive live vaccines (e.g., MMR, nasal flu, yellow fever) while on CIMZIA. Discuss vaccination schedule with your doctor.,Report any signs of infection (fever, cough, painful urination) or allergic reactions (rash, difficulty breathing) immediately.,Store CIMZIA in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Allow to reach room temperature before injection.,Use proper injection technique; rotate injection sites (abdomen, thigh). Discard unused portions in a sharps container.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. CIMZIA has low placental transfer and may be used during pregnancy.
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFUZOSIN HYDROCHLORIDE vs CIMZIA, answered by our medical review team.
ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. CIMZIA is a TNF-alpha Inhibitor that works by Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFUZOSIN HYDROCHLORIDE and CIMZIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. The standard adult dose of CIMZIA is: 400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFUZOSIN HYDROCHLORIDE and CIMZIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. CIMZIA is classified as Category C. CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no incr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.